Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
OHSU Knight Cancer Institute
invoX Pharma Limited
Providence Health & Services
Deciphera Pharmaceuticals, LLC
Jules Bordet Institute
GI Innovation, Inc.
Nektar Therapeutics
Chinese PLA General Hospital
Novartis
King Faisal Specialist Hospital & Research Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chinese PLA General Hospital
Daiichi Sankyo
AstraZeneca
Synta Pharmaceuticals Corp.
National Institutes of Health Clinical Center (CC)